PNPLA3 and metabolic dysfunction-associated steatotic liver disease: These words include hyperinsulinemia, glucose intolerance, hypertriglyceridemia as terms related to the claims from research performed from 2004 until 2007, that associated PNPLA3 with obesity, insulin resistance in adipose tissues32–34, the phenotypes of NAFLD.